Heron Therapeutics Inc vs Intuitive Surgical, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while Intuitive Surgical, Inc. trades at $418.69 (market cap $146.76B). The key difference: Intuitive Surgical, Inc. is far larger — about 2157.9× Heron Therapeutics Inc's market cap, and Intuitive Surgical, Inc. is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Intuitive Surgical, Inc. for 84 Days on average.
| HRTX | ISRG | |
|---|---|---|
Market Cap | $68.01M | $146.76B |
Volume | 1,891,941 | 2,529,814 |
Sector | Health | Health |
52-Week High | $1.49 | $592.85 |
52-Week Low | $0.27 | $332.02 |
Typical Hold Time | 35 Days | 84 Days |
Enterprise Value | $174.75M | $141.54B |
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Intuitive Surgical (ISRG) trades at $414.52, up 2.41% with strong bullish technical signals and consistent earnings beats. The company demonstrates robust fundamentals with 2025 revenue reaching $10.06 billion and net income of $2.86 billion, maintaining impressive profit margins above 28%. Recent expansion into ambulatory surgery centers and international markets like India and Japan provides growth catalysts, though China headwinds present challenges. Technical indicators show bullish momentum with support at $411 and resistance at $417.
ISRG presents a compelling growth story with dominant market positioning in robotic surgery and strong recurring revenue streams. The stock offers 16% upside to the consensus price target of $480.78, supported by 70% analyst buy ratings. Key risks include competitive pressures in robotic surgery and international market volatility. The company's consistent earnings outperformance and expanding global footprint suggest continued growth potential despite near-term headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →